MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- BIOCON - DR. REDDYS LAB
BIOCON vs DR. REDDYS LAB - Comparison Results
BIOCON Change
Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More
DR. REDDYS LAB 
Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More
Current Valuations
| BIOCON | DR. REDDYS LAB | BIOCON / DR. REDDYS LAB |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 19.3 | 23.1 | 83.6% | View Chart |
| P/BV | x | 3.0 | 3.2 | 96.6% | View Chart |
| Dividend Yield | % | 0.4 | 0.8 | 50.7% |
Financials
 BIOCON  DR. REDDYS LAB |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| BIOCON Mar-18 |
DR. REDDYS LAB Mar-19 |
BIOCON / DR. REDDYS LAB |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,188 | 2,875 | 41.3% | |
| Low | Rs | 305 | 1,888 | 16.2% | |
| Sales per share (Unadj.) | Rs | 68.7 | 930.2 | 7.4% | |
| Earnings per share (Unadj.) | Rs | 7.6 | 117.4 | 6.4% | |
| Cash flow per share (Unadj.) | Rs | 14.0 | 185.8 | 7.5% | |
| Dividends per share (Unadj.) | Rs | 1.00 | 20.00 | 5.0% | |
| Dividend yield (eoy) | % | 0.1 | 0.8 | 16.0% | |
| Book value per share (Unadj.) | Rs | 86.3 | 844.4 | 10.2% | |
| Shares outstanding (eoy) | m | 600.00 | 166.07 | 361.3% | |
| Bonus/Rights/Conversions | IS | ESOP | - | ||
| Price / Sales ratio | x | 10.9 | 2.6 | 424.3% | |
| Avg P/E ratio | x | 98.9 | 20.3 | 487.4% | |
| P/CF ratio (eoy) | x | 53.4 | 12.8 | 416.8% | |
| Price / Book Value ratio | x | 8.6 | 2.8 | 306.6% | |
| Dividend payout | % | 13.2 | 17.0 | 77.7% | |
| Avg Mkt Cap | Rs m | 447,900 | 395,496 | 113.3% | |
| No. of employees | `000 | 6.1 | 22.0 | 28.0% | |
| Total wages/salary | Rs m | 9,311 | 33,562 | 27.7% | |
| Avg. sales/employee | Rs Th | 6,705.8 | 7,032.8 | 95.4% | |
| Avg. wages/employee | Rs Th | 1,514.2 | 1,527.9 | 99.1% | |
| Avg. net profit/employee | Rs Th | 736.9 | 887.7 | 83.0% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 41,234 | 154,482 | 26.7% | |
| Other income | Rs m | 2,062 | 3,375 | 61.1% | |
| Total revenues | Rs m | 43,296 | 157,857 | 27.4% | |
| Gross profit | Rs m | 8,291 | 31,782 | 26.1% | |
| Depreciation | Rs m | 3,851 | 11,348 | 33.9% | |
| Interest | Rs m | 615 | 889 | 69.2% | |
| Profit before tax | Rs m | 5,887 | 22,920 | 25.7% | |
| Minority Interest | Rs m | 213 | 0 | - | |
| Prior Period Items | Rs m | 0 | 438 | 0.0% | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 1,569 | 3,858 | 40.7% | |
| Profit after tax | Rs m | 4,531 | 19,500 | 23.2% | |
| Gross profit margin | % | 20.1 | 20.6 | 97.7% | |
| Effective tax rate | % | 26.7 | 16.8 | 158.3% | |
| Net profit margin | % | 11.0 | 12.6 | 87.1% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 41,486 | 111,101 | 37.3% | |
| Current liabilities | Rs m | 21,413 | 58,973 | 36.3% | |
| Net working cap to sales | % | 48.7 | 33.7 | 144.3% | |
| Current ratio | x | 1.9 | 1.9 | 102.8% | |
| Inventory Days | Days | 64 | 79 | 80.6% | |
| Debtors Days | Days | 94 | 94 | 100.0% | |
| Net fixed assets | Rs m | 50,661 | 101,245 | 50.0% | |
| Share capital | Rs m | 3,000 | 830 | 361.4% | |
| "Free" reserves | Rs m | 48,808 | 139,406 | 35.0% | |
| Net worth | Rs m | 51,808 | 140,236 | 36.9% | |
| Long term debt | Rs m | 17,898 | 22,000 | 81.4% | |
| Total assets | Rs m | 99,897 | 224,656 | 44.5% | |
| Interest coverage | x | 10.6 | 26.8 | 39.5% | |
| Debt to equity ratio | x | 0.3 | 0.2 | 220.2% | |
| Sales to assets ratio | x | 0.4 | 0.7 | 60.0% | |
| Return on assets | % | 5.2 | 9.1 | 56.8% | |
| Return on equity | % | 8.7 | 13.9 | 62.9% | |
| Return on capital | % | 9.6 | 14.9 | 64.5% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 12,058 | 88,673 | 13.6% | |
| Fx outflow | Rs m | 7,348 | 19,104 | 38.5% | |
| Net fx | Rs m | 4,710 | 69,569 | 6.8% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 6,621 | 28,704 | 23.1% | |
| From Investments | Rs m | -6,840 | -7,727 | 88.5% | |
| From Financial Activity | Rs m | -2,397 | -21,326 | 11.2% | |
| Net Cashflow | Rs m | -2,612 | -314 | 831.8% | |
Share Holding
| Indian Promoters | % | 40.4 | 25.5 | 158.4% | |
| Foreign collaborators | % | 20.6 | 0.0 | - | |
| Indian inst/Mut Fund | % | 8.4 | 5.4 | 155.6% | |
| FIIs | % | 10.7 | 35.3 | 30.3% | |
| ADR/GDR | % | 0.0 | 18.5 | - | |
| Free float | % | 19.9 | 15.3 | 130.1% | |
| Shareholders | 109,995 | 75,885 | 144.9% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BIOCON With: ELDER PHARMA FDC LTD. SHASUN PHARMA STRIDES PHARMA SCIENCE J.B.CHEMICALS
Compare BIOCON With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Indian Indices End on a Positive Note for Third Straight Day; Yes Bank Falls 5%(Closing)
Indian share markets traded on a positive note most of the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the IT sector.
Related Views on News
BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)
Apr 26, 2019 | Updated on Apr 26, 2019For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)
Feb 4, 2019 | Updated on Feb 4, 2019For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.
BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)
Jan 28, 2019 | Updated on Jan 28, 2019For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.
BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)
Nov 9, 2018 | Updated on Nov 9, 2018For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.
BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)
Jul 30, 2018 | Updated on Jul 30, 2018For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.
More Views on NewsMost Popular
These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)
Jul 9, 2019As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.
2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)
Jul 12, 2019Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.
A One Stock Crorepati(Profit Hunter)
Jul 4, 2019Do you wish you could become a crorepati in the stock market? Read on...
After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)
Jul 8, 2019A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...
Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)
Jul 5, 2019Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?
More|
| |
BIOCON SHARE PRICE
Jul 17, 2019 (Close)
TRACK BIOCON
- Track your investment in BIOCON with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON BIOCON
BIOCON - PANACEA BIOTECH COMPARISON
COMPARE BIOCON WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.